LCT reports long-term insulin uptake
Wednesday, 25 June, 2008
Auckland-based Living Cell Technologies (ASX: LCT) has reported that patients undergoing clinical trials of the company's DiabeCell encapsulated porcine insulin-producing cells had porcine insulin in their blood samples six and 11 months after implantation.
Living Cell had already proven that the two patients, both from its Phase I/IIa trial in Russia, who were implanted with DiabeCell, required a lower insulin dose to manage the illness. The female patient had detectable levels of porcine insulin after she stopped insulin injections.
LCT's CEO Dr Paul Tan said the data was consistent with published research showing that porcine insulin was present in a NZ patient 10 years after implantation.
"This has now been validated again after 11 months without use of immunosuppressive drugs in the current trial and at the lowest dose of DiabeCell," Tan said.
Preliminary data from three other patients is yet to be reported.
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
